Dr Reddy’s shares jump 6% on Q3 FY26 results beat

Stock jumps after results surprise

Dr Reddy’s Laboratories shares rallied on Thursday after the company reported stronger-than-expected results for the third quarter of FY26, leading some brokerages to turn more constructive on the stock. The gains came despite a year-on-year decline in consolidated net profit, as investors focused on revenue resilience and operating commentary. The market response also reflected expectations of regulatory catalysts tied to the company’s pipeline, including GLP-1 opportunities. Brokerages pointed to better-than-expected momentum in India and certain international markets as an offset to ongoing headwinds in North America.

Thursday’s trade: price action and key levels

On the National Stock Exchange (NSE), Dr Reddy’s Laboratories Ltd was trading at INR 1,222.70, up INR 65.50 or 5.66% as of 12:27 pm on 22 January 2026. The stock opened at INR 1,195 and moved to an intraday high of INR 1,225. The session low was INR 1,187.70. The sharp move indicated a clear reassessment by the market after the quarterly print and subsequent brokerage notes.

Profit falls year-on-year, but the market looks through it

For the December quarter, the company reported a 14.4% year-on-year decline in consolidated net profit to INR 12,098 million. The reported decline was set against the backdrop of product and geography-level shifts, including pressure from a lower contribution from Lenalidomide sales, as referenced in management commentary. Investors appeared to place greater weight on revenue delivery and the outlook for approvals and launches than on the headline profit decline.

Revenue beats expectations on India and emerging markets

Revenue from operations rose 4.4% year-on-year to INR 87,268 million, driven largely by growth in India and emerging markets. The article noted that revenue growth exceeded market expectations, supported by robust performance in India, Europe, and emerging markets. At the same time, Dr Reddy’s continued to face challenges in its North American business, which remains an area investors track closely given its historical contribution and the volatility typical of US generics.

Management commentary: branded momentum and forex tailwind

Co-Chairman and Managing Director G V Prasad attributed Q3FY26 growth to continued momentum in the company’s branded businesses, supported by favourable foreign exchange. He said this helped offset the impact of lower Lenalidomide sales. Management reiterated its focus on disciplined execution of strategic priorities including base business growth, pipeline advancement, operational efficiencies, and selective inorganic opportunities. The commentary framed the quarter as one where execution in core markets and currency benefits helped absorb product-level pressures.

Brokerages turn more constructive; HSBC reiterates Buy

Brokerage houses adopted a more positive stance following the results. HSBC retained a “buy” rating and set a target price of INR 1,435 in the post-results commentary referenced in the article. HSBC highlighted stronger-than-expected sales growth in India and Russia, along with favourable foreign exchange benefits. It also pointed to regulatory approvals as key catalysts for the stock in the near term.

Regulatory catalysts in focus: semaglutide and abatacept

Two developments were highlighted as near-term triggers: the generic semaglutide approval in Canada, and the abatacept biosimilar (IV formulation) in the US. Investors are monitoring timelines because timely clearances could influence market sentiment and incremental earnings visibility. While the company’s North America business remains challenging, these pipeline events are watched as potential offsets and medium-term growth levers.

GLP-1 remains a key theme in HSBC’s separate note

In a separate “Equity Alert” cited in the provided text, HSBC Global maintained a buy rating on Dr Reddy’s with a target price of INR 1,430, according to a CNBC-TV18 post on X. The brokerage noted that glucagon-like peptide-1 (GLP-1) drugs remain a focus segment for the company and that long-term growth drivers are progressing. The same note said the generic semaglutide opportunity in Canada remains intact, and that Dr Reddy’s has responded to queries from Health Canada on its application.

What happened in Canada: notice of non-compliance and market size

The CNBC-TV18 post said Dr Reddy’s injectable semaglutide launch in Canada was delayed after Canada’s Pharmaceutical Drugs Directorate issued a notice of non-compliance on the company’s abbreviated new drug submission on 30 October. The post cited estimated annual semaglutide sales of USD 1,600 million in Canada. It also said the company is confident of achieving at least USD 300 million in revenue from semaglutide in the initial phase, if approvals and launch plans proceed.

Key numbers at a glance

Market impact: what investors are reacting to

The immediate market reaction centred on two points: revenue strength outside North America and clearer visibility on pipeline-related catalysts. The quarter showed that growth in India, Europe, and emerging markets can provide support when the North America business is under pressure. Broker commentary, particularly around GLP-1 opportunities, reinforced the idea that the market is attaching value to regulatory outcomes rather than only near-term profit volatility. Price action on the day reflected this shift, with the stock moving close to the intraday high after opening higher.

Why this matters for Dr Reddy’s narrative

The results and the subsequent brokerage stance highlight how Dr Reddy’s investment debate is evolving toward growth drivers beyond legacy products. Management’s reference to lower Lenalidomide sales shows that product-cycle impacts are still present, but the company is positioning around branded momentum, forex benefits, and pipeline advancement. HSBC’s emphasis on semaglutide and other approvals underscores how regulatory milestones can influence expectations for the next leg of earnings and revenue trajectory.

Conclusion

Dr Reddy’s shares rose nearly 6% on 22 January 2026 as investors responded to Q3 FY26 revenue that exceeded expectations and to more constructive brokerage commentary. While net profit fell year-on-year, the market focus stayed on strength in India and emerging markets and the prospect of regulatory catalysts. Near-term attention is likely to remain on timelines for the generic semaglutide decision in Canada and the abatacept biosimilar (IV) in the US, as highlighted by broker notes and the company’s pipeline watchlist.